Showing results (121-130 of 250) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Neurotoxicity of CI-980, a novel mitotic inhibitorC A Meyers, A P Kudelka, C A Conrad, et al.Investigational New Drugs|November 1, 1991
Phase I trial of FK973: description of a delayed vascular leak syndromeR Pazdur, D H Ho, K Daugherty, et al.Oncology Nursing Forum|January 1, 1991
5-Fluorouracil and recombinant interferon alfa-2a: review of activity and toxicity in advanced colorectal carcinomasR Pazdur, D Jackson, B Shepherd, et al.American Journal of Clinical Oncology|December 10, 1997
Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicityR Pazdur, C Meyers, E Diaz-Canton, et al.Cancer|July 1, 1975
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinomaP Seifert, L H Baker, M L Reed, et al.American Journal of Clinical Oncology|December 1, 1996
Phase II study of ZD1694 in patients with advanced gastric cancerN J Meropol, R Pazdur, M Vincent, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 1998
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracilD H Ho, R Pazdur, W Covington, et al.Anti-Cancer Drugs|January 12, 2000
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumorsR A Newman, J Kim, B M Newman, et al.Anticancer Research|March 1, 1993
Clinical pharmacology of 11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo (7.4.1.0(2,7).0(10,12) tetradeca-2,4,6-trien-6,9-diyl diacetate (FK 973)D H Ho, R Pazdur, N S Brown, et al.Cancer Chemotherapy and Pharmacology|January 1, 1990
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patientsG G Chabot, L E Flaherty, M Valdivieso, et al.Pageof 25